University of Maryland Baltimore County

Launchpad's Network All Roads Travel (ART) Will Help Raise Brand Awareness for Safety Shot Among Millions of U.S. College Students JUPITER, Fla., Sept. 19, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) ("Safety Shot" or "the Company"), a wellness company behind the first patented wellness product on Earth that lowers blood alcohol content in as little as 30 minutes by supporting its metabolism, has partnered with Launchpad, a dynamic marketing agency that specializes in college student-focused marketing solutions. The Company will be utilizing Launchpad's network All Roads Travel (ART), the #1 College Tour Operator in the nation, to raise brand awareness for the Safety Shot product among college students. ART's campaigns have a nationwide reach spanning over 100 major campuses across the United States. These campaigns tap into thousands of existing student ambassadors, providing brands direct access to highly engaged student communities. ART has successfully executed campaigns with renowned brands such as Fashion Nova, Celsius, 818 Tequila, and more, with a focus on college markets. Ambassadors are influential both online and offline, creating organic content across key platforms including Tik Tok. As part of the Safety Shot partnership, ATR will leverage peer-to-peer marketing, product trials, and will engage in ambassador-led activities on campuses and on social media. Ambassadors will organize events, manage product sampling, create and share content, and build communities that promote the Safety Shot brand across their campuses. College students are educated, brand-loyal consumers. The college market is geographically stable and there are over 21 million college students enrolled across the country boasting a whopping $593 billion in spending power.1 "This partnership will drive organic awareness, growth, and engagement for Safety Shot, establishing it as a must-have product among college students," said Safety Shot CEO Jarett Boon. "With years of experience managing large-scale ambassador teams, ART has a deep understanding of the college demographic. With roughly 20 million college students in the U.S., the potential for the Safety Shot brand to win big with this generation is huge. This is a specific market that loves to have fun but also needs to study and pass their exams. Safety Shot promotes rapid alcohol detoxification and sobriety. This partnership could help us achieve remarkable brand awareness with one of the biggest demographics in the country," Boon added. "We're excited to partner with Safety Shot and bring their unique product to life on some of the most influential college campuses across the country. This partnership represents a great opportunity to harness the power of peer-driven marketing and build lasting brand loyalty among students," stated the Director of Partnerships & Growth at All Roads Travel. ART and Safety Shot plan to expand the ambassador program to additional campuses over time, which will increase brand visibility and engagement. By combining ART's expertise in student engagement with Safety Shot's innovative product, the partnership holds strong potential for long-term growth and expansion across the college market. For more information on Safety Shot, visit and Amazon. About Safety Shot, Inc. Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024. Forward-Looking Statements This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's Form 10-Q for the fiscal year ended June 30, 2024, filed with the Securities and Exchange Commission on August 15, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law. 1 . SOURCE Safety Shot WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Leading Neuroscientists, Technologists, Regulators, and Venture Capitalists Convening in West Virginia MORGANTOWN, W.Va., Aug. 9, 2024 /PRNewswire/ -- West Virginia University (WVU) Medicine will host an international gathering of scientists, engineers, researchers, physicians, and industry leaders at the Brain-Machine Interface (BMI) Summit this coming weekend. Organized by Dr. Peter Konrad of WVU Medicine and Dr. Jose "Pepe" Contreras-Vidal of the University of Houston, the event is a key programming component of the National Science Foundation's (NSF) Industry-University Cooperative Research Centers (IUCRC). The conference aims to advance the accessibility and sustainability of BMI technologies for patients with neurological conditions by underscoring the need for increased collaboration across industry, government, and university systems. The BMI Summit will feature presentations and panel discussions with prominent figures from the FDA, NIH, NSF, and VA, alongside industry leaders from companies including Blackrock Neurotech, Precision Neuroscience, and Synchron. Three pioneering patients – Ian Burkhardt, Nathan Copeland, and Jen French – who have been at the forefront of BMI device trials, demonstrating the transformative potential of these technologies will be sharing their crucial patient perspective for those dealing with disabling conditions like paralysis, stroke, speech loss, vision loss, pain, and brain injury. "For 20 years, we've seen incredible advancements in BMI technology, but the journey from laboratory to bedside has too often been slow and fragmented," said Dr. Konrad. "This summit is about changing that trajectory and delving beyond established science and technology to focus on transforming innovative research into real-world applications." Ben Rapoport, Co-Founder and Chief Science Officer at Precision Neuroscience, emphasized, "The innovations happening in neurotechnology today are not just incremental—they're potentially transformative. This gathering is about harnessing those innovations and turning them into scalable, clinically viable solutions. It's a crucial step in making the science of today the standard of care tomorrow." Prior to the weekend's agenda, the initial two days (August 8-9) are dedicated to a closed, invite-only session for members of the NSF research consortium, composed of five universities: University of Houston, Arizona State University, West Virginia University, University of Maryland Baltimore County, and Georgia Tech. "We're not here to discuss what's possible; we're here to determine how we can make it happen," continued Dr. Konrad. Following the conference, a comprehensive white paper will be produced outlining actionable steps for advancing BMI technologies from experimental phases to widespread clinical use. "This summit covers critical topics that ensure the future of neurotechnology," said Rob Franklin, Senior VP of Brain-Computer Interface at Blackrock Neurotech. "The collaborative efforts of leading researchers, industry experts, and regulatory bodies are essential to safely and effectively push the boundaries of what's possible and bring innovative solutions to those who need them most. By working together, we can accelerate the development and deployment of BMI technologies, ultimately improving the quality of life for countless individuals and their families." Event Details: Date: August 10-11, 2024 Location: Marriott, Morgantown, WV Website: Registration: Required, with applicable fees About the West Virginia University Rockefeller Neuroscience Institute The WVU Rockefeller Neuroscience Institute (RNI) is a comprehensive multidisciplinary patient care, education, and research institute providing neurological and mental healthcare for 275,000 patients annually. The 250 physicians and scientists of the RNI improve lives by pioneering advances in neuroscience, brain health, and therapeutics. The RNI team uses the latest technologies with academic, government, and industry partners to make tangible progress to combat public health challenges ranging from addiction to Alzheimer's disease. For more information about the WVU Rockefeller Neuroscience Institute, visit WVUMedicine.org/RNI. Media Contact: Kate Salo, 215-806-9332 or [email protected] SOURCE WVU Medicine

PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors. Mr. Gathagan is the owner and a managing member of broad Thinking, LLC, a management consulting firm and has 25 years of animal health experience. He is a founding member of Animalytix LLC and has served as its Chief Financial and Chief Technology Officer since it began operations in 2010. Prior to Animalytix, he was a senior executive and Vice President of IT and Finance for Intervet, Inc. and oversaw various finance, IT, and general business functions between 1998 to 2008, including 3 years in a global role based in The Netherlands. Before entering the animal health industry, he served as a Vice President at MBNA and Norwest Bank responsible for various IT functions and started his career in IT roles at the University of Maryland, Baltimore County (UMBC). He holds a BS in Information Systems Management from UMBC and an MS in Business from Johns Hopkins University. “Bryan’s depth of experience in the animal health industry and his financial skills will be a great asset to ImmuCell,” commented Michael F. Brigham, President and CEO of ImmuCell. “We all look forward to working with him and adding his perspective to our business operations and strategies.” “I’m excited to be joining ImmuCell’s Board of Directors, and I look forward to supporting Michael and the rest of ImmuCell’s leadership team,” added Mr. Gathagan. About ImmuCell:ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com. Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):This Press Release contains or may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. These statements are intended to provide management's current expectation of future events as of the date of this Press Release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Contacts: Michael F. Brigham, President and CEOImmuCell Corporation (207) 878-2770Joe Diaz, Robert Blum and Joe DorameLytham Partners, LLC(602) 889-9700iccc@lythampartners.com